Archive · 30 Jul 2026
ChrysCapital Acquires Majority Stake in Novartis India, Rebrands Company
A private‑equity company called ChrysCapital bought most of a drug company in India that used to belong to a Swiss company.
They paid about 1,446 crore rupees for it.
Now the Indian company will have a new name and run on its own.
A new boss, Dr Vikas Gupta, will lead it.
ChrysCapital wants to grow the company by making more generic medicines for people in India.
Private equity firm ChrysCapital has acquired a 70.68% controlling stake in Novartis India Limited (NIL) from its parent company Novartis AG.
The deal, valued at ₹1,446 crore, marks ChrysCapital’s first majority investment in India’s pharmaceutical sector.
NIL will rebrand and operate independently, focusing on building a leading branded‑generics platform across multiple therapeutic areas.
New leadership includes Dr Vikas Gupta as CEO/MD and independent directors Ramesh Ramadurai, Suchita Sharma, and Shashank Sinha.
The transaction was advised by Kotak, Freshfields, AZB & Partners, Ernst & Young, Shardul Amarchand Mangaldas & Co, Alvarez & Marsal, Dhruva Advisors, and Price Waterhouse & Co.
- Who
- Private equity firm ChrysCapital and Swiss drugmaker Novartis AG
- What
- Acquisition of a 70.68% controlling stake in Novartis India Limited
- When
- July 30, 2026
- Where
- India
- Why
- To build a leading branded‑generics platform and separate NIL from its parent
- Stake acquired
- 70.68%
- Deal value
- ₹1,446 crore
- New CEO
- Dr Vikas Gupta
- New name
- TBD
- Date
- July 30, 2026